OMCL 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-06

• •unfavorable general economic and market conditions, including the potential impact of inflationary pressures;

• •our ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions;

• •reductions in demand in the capital equipment market or reductions in the demand for, or adoption of, our solutions, systems, or services;

• •our ability to successfully achieve anticipated growth targets or market adoption;

• •delays, technical challenges and unexpected or greater than anticipated expenses associated with developing new products and services or failing to achieve technological or economic feasibility, obtain regulatory approval or gain market acceptance resulting in stopping the development of, or the co…

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• •our ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, including incorporating artificial intelligence (“AI”) technology and the use of AI by our vendors and competitors;

• •reductions in demand in the capital equipment market or reductions in the demand for or adoption of our solutions, systems, or services;

• •transitioning to selling more products and services on a subscription basis;

• •failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers;

• •meeting the demands of, or maintain relationships with, institutional, retail, and specialty pharmacy customers;

相对上期新增的文字 · 来源:10-Q · 2026-05-06

• We operate in foreign countries which expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which are the British Pound and the

• Euro. In order to manage foreign currency risk, at times we enter into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries. In general, the market risk rela…

• We are exposed to interest rate risk through our borrowing activities. As of March 31, 2026, there was no outstanding balance under the current Second A&R Credit Agreement. Refer to Note 10, Debt and Credit Agreement, of the Notes to Condensed Consolidated Financial Statements included in this Quart…

• As of March 31, 2026, the net carrying amount under the 2029 Notes was $167.9 million. Although our convertible senior notes are based on a fixed rate, changes in interest rates could impact the fair value of such notes. As of March 31, 2026, the fair market value of the 2029 Notes was $167.4 millio…

• We have used, and in the future we may use, interest rate swap agreements to protect against adverse fluctuations in interest rates by reducing our exposure to variability in cash flows relating to interest payments on a portion of our outstanding debt. We do not hold or issue any derivative financi…

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• We operate in foreign countries which expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which are the British Pound and the Euro. In order to manage foreign currency risk, at times we e…

• We are exposed to interest rate risk through our borrowing activities. As of September 30, 2025, there was no outstanding balance under the current Second A&R Credit Agreement. Refer to Note 10, Debt and Credit Agreement, of the Notes to Condensed Consolidated Financial Statements included in this Q…

• As of September 30, 2025, the net carrying amount under the 2029 Notes was $167.3 million. Although our convertible senior notes are based on a fixed rate, changes in interest rates could impact the fair value of such notes. As of September 30, 2025, the fair market value of the 2029 Notes was $159.…

• We have used, and in the future we may use, interest rate swap agreements to protect against adverse fluctuations in interest rates by reducing our exposure to variability in cash flows relating to interest payments on a portion of our outstanding debt. We do not hold or issue any derivative financi…

• There were no significant changes in our market risk exposures during the nine months ended September 30, 2025 as compared to the market risk exposures disclosed in “Quantitative and Qualitative Disclosures About Market Risk,” set forth in Part II, Item 7A of our Annual Report on Form 10-K for the y…

相对上期新增的文字 · 来源:10-Q · 2026-05-06

• During the three months ended March 31, 2026, Nnamdi Njoku, the Company’s Executive Vice President and Chief Operating Officer, adopted a new “Rule 10b5-1 trading arrangement” (as defined in Item 408(a) of Regulation S-K) on February 9, 2026, which is intended to satisfy the Rule 10b5-1(c) affirmati…

• In addition, on February 23, 2026, Randall A. Lipps, the Company’s President, Chief Executive Officer, and Chairman of the Board of Directors, terminated a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, which was previously adopted on Ma…

• The actions described above were adopted and precleared in accordance with the Company’s Insider Trading Policy and actual sale transactions made pursuant to such trading plans will be disclosed publicly in future Section 16 filings with the SEC.

• Other than as disclosed above, none of our other directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or adopted or terminated a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408(a) of Regulation S-K) during the three months ended March 31, 2026.

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• During the three months ended September 30, 2025, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or adopted or terminated a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408(a) of Regulation S-K).